Overall survival of first-line amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.

作者：Joel W. Neal, B K Cho, Yongsheng Wang, Lin Wu, Enriqueta Felip, Jiuwei Cui, A Spira, Melina E. Marmarelis, Eiki Ichihara, Se-Hoon Lee, James Chih Hsin Yang, Sebastian Michels, Joshua C. Curtin, Xuesong Lu, Zacharias Anastasiou, Isabelle Leconte, Leonardo Trani, Sujay Shah, Pascale Tomasini · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.16_suppl.8501 · 被引用次数：4 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Radiomics and Machine Learning in Medical Imaging

8501 Background: Patients with atypical EGFR -mutated advanced NSCLC have worse long-term outcomes with EGFR-targeted therapies than classical exon 19 deletion/L858R mutations (c EGFR ). Afatinib, approved for atypical EGFR -mutated NSCLC, showed a median overall survival (OS) of 19.4 months among 38 participants (pts) with atypical EGFR- mutations globally (Yang Lancet Oncol 2015). Amivantamab (ami)-based regimens are approved across multiple lines of therapy in different settings for c EGFR and exon 20 insertion (Ex20ins)-mutated advanced NSCLC. In MARIPOSA, first-line (1L) ami plus lazertinib (ami-laz) significantly prolonged OS vs osimertinib (HR, 0.75; P =0.005) in c EGFR -mutated NSCLC. In an earlier report of 49 pts with atypical EGFR -mutated advanced NSCLC who received 1L ami-laz, objective response rate (ORR) was 57%, median response duration was 20.7 months, median progression-free survival (PFS) was 19.5 months, and OS was still immature (Tomasini JCO 2025). Here we report OS data with longer follow-up for pts with atypical EGFR -mutated NSCLC who received 1L ami-laz. Methods: Cohort C of the global, phase I/Ib CHRYSALIS-2 study (NCT04077463) enrolled pts with atypical EGFR mutations, excluding Ex20ins and co-mutations with c EGFR , who were previously untreated or had ≤2 prior lines of therapy, which may have included a 1 st /2 nd -generation EGFR TKI. All enrolled pts received intravenous ami-laz. The primary endpoint was ORR by investigator per RECIST v1.1, whi...